Developing a new treatment for severe mouth sores in cancer patients
IND-enabling toxicology studies to reach IND approval for a proprietary biologic to treat oral mucositis in cancer patients
This study is testing a new gel treatment for mouth sores that can happen during cancer radiation therapy, aiming to help patients heal better and feel more comfortable while they receive their treatment.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Allander Biotechnologies, INC. NIH-funded |
| Lab location | 1 site (Aurora, United States) |
| Project ID | NIH-10933015 on NIH RePORTER |
What this research studies
This research focuses on creating a new biologic treatment for oral mucositis, a painful condition that often affects cancer patients undergoing radiation therapy. The approach involves applying a specially formulated gel to the oral mucosa, which has shown promising results in preclinical trials with animals. The goal is to improve healing and reduce the severity of mouth sores, allowing patients to tolerate cancer treatments better. The research will also ensure that the treatment meets regulatory standards for safety and efficacy.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients undergoing radiation therapy who are at risk of developing oral mucositis.
Not a fit: Patients who are not undergoing radiation therapy or who do not develop oral mucositis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new effective treatment option for cancer patients suffering from oral mucositis, improving their quality of life and treatment outcomes.
How similar studies have performed: Previous research has shown success with similar biologic treatments in animal models, indicating potential for effective application in humans.
Where this research is happening
Aurora, United States
- Allander Biotechnologies, INC. — Aurora, United States (Active)
Researchers
- Principal investigator: Young, Christian — Allander Biotechnologies, INC.
- Study coordinator: Young, Christian
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.